Bristol Myers Squibb (BMY) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $2.2 billion.
- Bristol Myers Squibb's Income from Continuing Operations rose 8065.84% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year increase of 18342.76%. This contributed to the annual value of -$8.9 billion for FY2024, which is 21110.7% down from last year.
- Bristol Myers Squibb's Income from Continuing Operations amounted to $2.2 billion in Q3 2025, which was up 8065.84% from $1.3 billion recorded in Q2 2025.
- Over the past 5 years, Bristol Myers Squibb's Income from Continuing Operations peaked at $2.5 billion during Q1 2025, and registered a low of -$11.9 billion during Q1 2024.
- In the last 5 years, Bristol Myers Squibb's Income from Continuing Operations had a median value of $1.7 billion in 2024 and averaged $970.3 million.
- As far as peak fluctuations go, Bristol Myers Squibb's Income from Continuing Operations skyrocketed by 142625.0% in 2021, and later plummeted by 62527.57% in 2024.
- Over the past 5 years, Bristol Myers Squibb's Income from Continuing Operations (Quarter) stood at $2.4 billion in 2021, then decreased by 14.63% to $2.0 billion in 2022, then dropped by 12.99% to $1.8 billion in 2023, then plummeted by 95.69% to $76.0 million in 2024, then skyrocketed by 2788.16% to $2.2 billion in 2025.
- Its Income from Continuing Operations was $2.2 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $2.5 billion in Q1 2025.